Method Article

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

8.1K views

⸱

DOI:

10.3791/54460

⸱

September 13th, 2016

 ,  ,  ,  ,  , 
1Department of Medicine B, University Hospital Münster, 2Institute of Palliative Care, University Hospital Münster, 3Biomedical Technology Center, University of Münster, 4Department of Gastroenterology, Klinikum Bielefeld

* These authors contributed equally

In This Article

Summary

Accurate assessment of anti-inflammatory effects is of utmost importance for the evaluation of potential new drugs for the treatment of inflammatory bowel disease. Digital holographic microscopy provides assessment of inflammation in murine and human colonic tissue samples as well as automated multimodal evaluation of epithelial wound healing in vitro.

Abstract

The incidence of inflammatory bowel disease, i.e., Crohn's disease and Ulcerative colitis, has significantly increased over the last decade. The etiology of IBD remains unknown and current therapeutic strategies are based on the unspecific suppression of the immune system. The development of treatments that specifically target intestinal inflammation and epithelial wound healing could significantly improve management of IBD, however this requires accurate detection of inflammatory changes. Currently, potential drug candidates are usually evaluated using animal models in vivo or with cell culture based techniques in vitro. Histological examination usually requires the cells or tissues of interest to be stained, which may alter the sample characteristics and furthermore, the interpretation of findings can vary by investigator expertise. Digital holographic microscopy (DHM), based on the detection of optical path length delay, allows stain-free quantitative phase contrast imaging. This allows the results to be directly correlated with absolute biophysical parameters. We demonstrate how measurement of changes in tissue density with DHM, based on refractive index measurement, can quantify inflammatory alterations, without staining, in different layers of colonic tissue specimens from mice and humans with colitis. Additionally, we demonstrate continuous multimodal label-free monitoring of epithelial wound healing in vitro, possible using DHM through the simple automated determination of the wounded area and simultaneous determination of morphological parameters such as dry mass and layer thickness of migrating cells. In conclusion, DHM represents a valuable, novel and quantitative tool for the assessment of intestinal inflammation with absolute values for parameters possible, simplified quantification of epithelial wound healing in vitro and therefore has high potential for translational diagnostic use.

Introduction

Inflammatory bowel disease (IBD), i.e., Ulcerative Colitis (UC) and Crohn's disease (CD) are idiopathic inflammatory disorders of the gastrointestinal tract1. Research into the underlying pathophysiology of IBD and the evaluation of potential new drugs or novel diagnostic approaches is particularly of importance. In both basic research and the clinical management of IBD patients, the intestinal mucosa has become a focus of attention2,3. The mucosa represents an anatomical boundary, at which the interaction between commensal bacteria, epithelial cells and various cellular components of the intestinal immune system orchestrate gut homeostasis4,5. However, in IBD patients, uncontrolled and persistent intestinal inflammation leads to mucosal damage, detectable as ulcerations or stenosis, which can finally culminate in breakdown of epithelial barrier function, which itself aggravates local inflammation6.

Epithelial wound healing is therefore crucial for epithelial regeneration following inflammation but is also a core requirement for the healing of gastrointestinal ulcers or anastomotic leakage after gastrointestinal surgery7. Epithelial wound healing can be simulated in in vitro wound healing assays and in murine models of intestinal inflammation8,9. Both in vitro and in vivo approaches have drawbacks, which limit the accuracy of experimental assessment. In vitro assays, like classical scratch assays, require protracted staining procedures or transfection with fluorescent chromophores. They are often limited by their discontinuous monitoring of cell proliferation and migration that cannot be automated10. In vivo models, such as dextran sodium sulphate (DSS)-induced colitis, frequently lack robust read-outs, in part due to the significant variation seen in laboratory markers, making such markers inappropriate to evaluate colitis severity11,12. Histological analysis of the inflamed mucosa is currently still the most valid approach to determine colitis severity but this, like in vitro epithelial wound healing assays, requires staining and is dependent on investigator's expertise13.

Recently digital holographic microscopy (DHM), a variant of quantitative phase microscopy14, was identified as useful tool for the evaluation of epithelial wound healing in vitro and in vivo15. DHM allows assessment of tissue density by measuring optical path length delay (OPD), which prospects novel cancer diagnosis16-18 and quantification of inflammation related tissue alterations19. Additionally, DHM allows monitoring of cell morphology dynamics by determining cell thickness, cell covered surface area and intracellular (protein) content quantity15,20. In in vitro assays, DHM also enables the analysis of physiological processes, e.g., cellular water permeability by evaluating changes in cell volume and thickness21,22. Moreover, DHM measurements can be automated which prevents investigator-associated sample bias.

Here, we demonstrate the use of DHM in a murine model of intestinal inflammation, and also apply DHM to analysis of human tissues samples for quantitative monitoring of wound healing as a label-free in vitro assay. First, we evaluate inflammatory alterations of different colonic wall-layers in colitic mice and tissue sections from humans with IBD. After describing the DHM quantitative phase imaging procedure, we provide detailed instructions for using the microscope components, the preparation of tissue sections and also describe the evaluation of the acquired quantitative phase images.

Next, we show that DHM can be utilized for continuous multimodal monitoring of epithelial wound healing in vitro, and describe the analysis of cellular characteristics like cell layer thickness, dry mass and cellular volume give insight into drug induced and physiologic cell alterations.

Access restricted. Please log in or start a trial to view this content.

Protocol

All animal experiments were approved by the regional ethics committee (the Landesamt für Natur, Umwelt und Verbraucherschutz, LANUV, Germany) according to German Animal Protection Law. The local ethics committee of the University of Münster approved the use of human tissues for histological and microscope analysis.

1. Animals and Materials

  1. Use female or male mice of the required DSS-susceptible strain that weigh 20 to 25 g, and house according to local animal care legislation. Provide special chow for rodents and autoclaved drinking water ad libitum.
  2. Induce acute DSS colitis by administering 3% w/v dextran sulfate sodium (DSS, molecular weight: 36,000-50,000 Da) in autoclaved tap water for 5 days.
    NOTE: The potency of DSS is highly variable depending on manufacturer and batch. Test your supplier-provided DSS first for induction of disease activity, for which daily body weight is a reliable and objective indicator.
  3. For histological evaluation of colonic tissue samples, euthanize mice by CO2 insufflation (or as specified by national and institutional guidelines) at the end of the experiment.

2. Experimental Setup for DSS-colitis and In-vitro Wound Healing Assays

  1. Cell culture and establishment of wound healing assay.
    1. Grow Caco-2 cells in a 95% humidity and 5% CO2 environment at 37 °C. Use RPMI medium with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
    2. Seed Caco-2 cells at a density of 4 x 105 cells/cm2 on 35 mm Petri dishes with high culture-insert (see Figure 4A).
      NOTE: The insert generates two cell covered areas that are separated with a defined cell free space representing the wounded area to be analyzed.
    3. Change medium two days after seeding. Perform by first aspirating residual medium with cell debris by using an automatic pipette, rinse with 100 µl of phosphate buffered saline (PBS) and add fresh RPMI medium or serum-deprived medium.
    4. Culture cells for 24 hr in serum-deprived medium (0.1% FBS) supplemented with 20 ng EGF/ml serum or 2 µg mitomycin c/ml serum to detect alterations in wound healing behavior. Add normal RPMI medium to control cells for 24 hr.
    5. After 24 hr of culture, remove and discard culture inserts as described in step 3.4 and perform DHM.
  2. Induction of acute DSS colitis
    1. Dissolve 3 g of DSS in 100 ml autoclaved water to get a 3% (w/v) DSS solution. Provide this solution in place of drinking water to mice ad libitum for 7 days. Calculate 5 ml of DSS-solution per mouse/day. Provide autoclaved water without DSS for control mice ad libitum.
  3. Preparation of cryostatic sections of murine and human colon
    1. Euthanize mice by CO2 insufflation at the end of the experiment.
    2. Dissect the animals' abdomen by laparotomy23. Remove the whole colon carefully using tweezers and cut the ileal and rectal end using surgical scissors. Cut the colon with a scissors longitudinally from the cecal to the rectal end and open the colon. Remove all feces from the specimen using tweezers followed by washing with PBS24.
    3. Prepare Swiss rolls by rolling up the whole colon with a cotton bud longitudinally from the cecal to the rectal end with the mucosa curved inwards. Embed colonic samples in optimal cutting temperature (OCT) compound and keep frozen at -80 °C until further use.
    4. Embed human colonic tissue from surgical specimen in optimal cutting temperature OCT compound and keep frozen at -80 °C until further use.
    5. Cut sections of 7 µm thickness of the OCT-compound-embedded specimens with the help of a cryotome just prior to examination.
      ​NOTE: The optimum sample thickness depends on the persistence and the scattering properties of the tissue type under investigation. For the described experiments using colon tissue, slice thickness > 10 µm cause significant increase in noise due to light scattering in quantitative DHM phase contrast images, while samples of thickness < 5 µm show a higher risk for damage induced artefacts from the cryo cutting process.
    6. Transfer sections on to a glass object carrier slide.

3. Technical Equipment, Software and Procedures for Acquisition and Evaluation of Digital Holograms

  1. Digital holographic microscope for quantitative cell and tissue imaging
    1. Use an off-axis Mach-Zehnder digital holographic microscopy system for live cell imaging25, as shown in Figure 1. Ensure that the microscope is equipped with a 10X microscope lens, a microscope stage with a holder for glass object carrier slides and Petri dishes with a diameter of 35 mm, a heating chamber to preserve physiological temperature at 37 °C and software for quantitative phase imaging25.
      NOTE: For example, as described in Kemper et al.26 and Langehanenberg et al.27.
      NOTE: Alternatively, use a similar system that is capable of performing bright field microscopy and quantitative phase imaging of living cells and dissected tissue slides.
    2. Clean microscope lens and condenser with lens cleaning paper and a cleaning agent (e.g., ethanol) as recommended by the manufacturer of the microscope to remove dust or other contaminations.
    3. Start the image acquisition software of the DHM microscope, select "bright field" imaging mode and switch "on" white light illumination. Ensure Köhler-illumination of the sample as recommended by the microscope manufacturer while observing the sample in the live imaging window of the image acquisition software (alternatively a standard image acquisition software can be used in this step).
      NOTE: The image intensity should be distributed homogeneously in the field of view and the sample position should not move during optical refocusing with the focus drive of the microscope.
    4. Select "DHM" imaging mode, turn "off" white light illumination and switch "on" the laser light. Check that the illumination with laser light is homogeneous (i.e., that light intensity is homogeneously distributed in the live imaging window of the imaging acquisition software of the DHM microscope) and observe that the off-axis carrier interference fringe pattern appears with adequate contrast in the captured images (digital holograms).
  2. Preparation of cryostat sections for imaging with DHM
    1. Take the sample (cryostat section on a glass object carrier, thickness: 7 µm, as described in 2.3) out of the freezer. Defrost the sample for about 5 min at RT and normal atmosphere.
    2. Add 50 - 100 µl phosphate buffered saline (PBS) as embedding medium onto the tissue section using a pipette until it is completely covered with buffer. Cover the sample with a clean glass cover slip (glass thickness 170 µm).
      NOTE: Over-drying can induce significant changes of the refractive index and scattering properties of the sample.
    3. Ensure that the bottom of the glass carrier and the cover slip are cleaned from dust and other contamination that may induce light scattering. The sample is ready for investigation with bright field microscopy and DHM.
  3. Quantitative phase imaging of tissue sections with DHM
    1. Switch on the digital holographic microscope, choose the 10X microscope lens for imaging. Start the image acquisition software of the DHM microscope and select bright file imaging mode.
    2. Place the tissue slide as described in 2) in the microscope slide holder, with the cover slip facing the microscope objective.
    3. Switch "on" the bright field illumination of the DHM microscope. Position the sample with the microscope stage and ensure that the tissue area of interest is visible in the live monitoring window. Improve the sharpness of the image using the microscope's focus drive.
      NOTE: As well as the area of interest, an area of slide without tissue should also be present in the field of view.
    4. Capture a bright field image of the sharply focused sample using the image acquisition software.
    5. Select "DHM" imaging mode, turn "off" the white light illumination and turn "on" the laser light illumination. Select the "exposure time" for hologram recording below 3 msec, observe that holographic off-axis interference fringes appear with adequate contrast in the live imaging window of the imaging acquisition software and capture a digital hologram.
    6. Repeat steps 3.3.3 - 3.3.5 until a sufficient number of bright field images and digital holograms of different sample areas have been recorded. Hologram acquisition is now complete.
  4. Preparation of wound healing assays for DHM imaging
    1. Switch on the Petri dish heating chamber of the DHM microscope about 1 - 3 hr prior to the start of the experiment to ensure stable temperature conditions during the DHM measurements.
    2. Prepare workbench with the required equipment (Petri dish for wound healing assay is described in 2.3): pipettes, tweezers, glass lid for Petri dish, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered cell culture medium with physiological temperature (37 °C) for sample preparation in sterile environment.
      ​NOTE: Dulbecco's Modified Eagle Medium (DMEM) is composed of 10 % fetal calve serum (FCS), 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), and 850 mg/L NaHCO3.
    3. Remove the plastic lid from the Petri dish and remove the cell culture medium with a pipette. Remove the insert from the Petri dish bottom using tweezers.
    4. Wash the sample 1 - 2 times with 1 ml HEPES buffered cell culture medium in order to remove dead cells and remaining cellular components (e.g., serum) in the wound area. Add 2 ml HEPES buffered cell culture medium and cap the Petri dish with the glass lid.
    5. Ensure that the glass lid and the Petri dish bottom have been cleaned from dust and other contamination. Sample is ready for time lapse observation with DHM.
  5. Continuous multimodal monitoring of wound healing in vitro with DHM
    1. Switch on the Petri dish heating chamber of the DHM microscope about 1 - 3 hr prior to the start of the experiment to ensure stable temperature conditions during the DHM measurements.
    2. Switch "on" the digital holographic microscope, select the 10X microscope lens for imaging. Start the image acquisition software of the DHM microscope and select "bright field" imaging mode. Ensure that the heating chamber for the Petri dish is operating a physiological temperature (37 °C).
    3. Place the Petri dish with the wound healing assay, prepared as described in 4), in the heating chamber of the DHM microscope.
    4. Select bright field imaging mode and position the sample with the microscope stage while observing it in the live monitoring window of the image acquisition software of the DHM microscope. Observe that the desired area of the sample appears sharply focused under white light illumination.
    5. Capture bright field images of different areas of the sample (wound area and surrounding areas with confluent cells) under white light illumination with the image acquisition software and document appearance, cell density and homogeneity.
    6. Select "bright field" imaging mode of the DHM microscope. Choose a suitable wound area under white light illumination in the live monitoring window with the image acquisition software of the DHM microscope. Ensure the wound area is free from dead cells and no serum remains, and ensure that both sides include a single homogeneous cell layer, preferably with straight borders.
    7. Capture a white light image of the initial wound area in bright field imaging mode with the image acquisition software of the DHM microscope.
    8. Turn "off" white light illumination, select "DHM" mode and switch "on" laser illumination. Select an exposure time of below 3 msec for hologram recording (observe that holographic off-axis interference fringes appear with adequate contrast in the live imaging window of the image acquisition software of the DHM microscope) and capture a digital hologram.
    9. Capture a sample hologram in DHM mode with the image acquisition software and reconstruct a quantitative phase image with the reconstruction software of the DHM microscope in order to check the image quality.
    10. Select a suitable time delay (e.g., 3 - 5 min) for time-lapse hologram acquisition with the image acquisition software of the DHM microscope.
    11. Select the time-lapse acquisition mode of the image acquisition software in which the sample is only illuminated with laser light during hologram acquisition.
    12. Start the time-lapse DHM observation of the wound healing assay.
    13. Stop the time-lapse acquisition after the intended time, select bright field imaging mode and document the final appearance of the sample under white light imaging.
  6. Reconstruct digital holograms of dissected tissues and determine the average refractive index as a parameter to quantify tissue density
    1. Reconstruct quantitative phase images from the digital holograms of dissected tissues with the software of the DHM microscope, e.g., as described in Kemper et al.26 and Langehanenberg et al.27.
    2. Determine the average phase contrast Δφ in different tissue layers (epithelium, submucosa, stroma) in appropriately chosen regions of interests (ROIs)19.
    3. Determine the refractive index of the embedding medium by using a refractometer or alternatively by using an appropriate value from the literature. (refractive index values for typical embedding media: nwater = 1.334 28, nPhosphate buffered saline (PBS) = 1.337 29, ncell culture medium = 1.337-1.339 29,30).
    4. Calculate the refractive indices of different tissue layers from the average phase contrast values19
      Refractive index formula diagram, showing ns calculation using optical path difference.     (1)
      NOTE: In Eq. 1 λ is the wavelength of the laser light (here: λ = 532 nm), d the thickness of the dissected tissues (here: 7 µm) and nmedium is the refractive index of the embedding medium (here: nmedium = nPBS = 1.337, determined by an Abbe-Refractometer).
  7. Reconstruct and evaluate digital holograms from the time-lapse wound healing series observation
    1. Reconstruct quantitative phase images from the time lapse hologram series obtained during wound healing observation with the DHM microscope software26,27.
    2. Normalize each series of quantitative phase images to the image with maximum phase contrast.
    3. Determine the area Sc that is covered by the cells in the quantitative DHM phase images by image segmentation, which can be performed using the free software cell profiler (www.cellprofiler.org31).
    4. Calculate the average phase contrast of the cells Δφcell in the area Sc.
    5. Retrieve the cellular dry mass DM from the average phase contrast Δφcell in the area Sc15
      Diffusion measurement formula DM=(10λ/2πα)ΔφcellSc equation; optics research calculation.     (2)
      NOTE: In Equation 2 DM denotes the cellular dry mass, Sc presents the area that is occupied by the cells and α = 0.002 m2/kg.
    6. Determine the integral cellular refractive index ncell and the refractive index of the cell culture medium nmedium. Determine ncell separately experimentally from suspended cells as described in 30 and measure nmedium with a refractometer. Alternatively use literature values for ncell30 and nmedium29,30.
    7. Calculate the average cell thickness dcell from λ, Δφcell, ncell and nmedium 26,32
      Static equilibrium formula for cell thickness; equation, optics, refractive index, phase difference.     (3)
      NOTE: In Eq. 3 the parameter dcell is the average cell thickness, λ denotes the light wavelength of the laser light, Δφcell denotes the average phase contrast, and ncell and nmedium are the integral cellular refractive index and the refractive index of the surrounding medium.

Access restricted. Please log in or start a trial to view this content.

Results

Typical Setup for DHM Imaging for Digital Holographic Microscopy (DHM)

To perform bright field imaging and quantitative DHM phase contrast imaging, we applied an inverted microscope as depicted in Figure 1B. The system was modified by attaching a DHM module, as described earlier25. Digital holograms were generated by illumination the sample with the l...

Access restricted. Please log in or start a trial to view this content.

Discussion

We demonstrate that DHM provides accurate assessment of histological damage in murine colitis models and human colonic tissue samples ex vivo. Furthermore, we shown DHM can continuously monitor epithelial wound healing whilst simultaneously providing multimodal information about cellular alterations. In DHM, the reconstruction of digitally captured holograms is performed numerically32. Therefore, in comparison to bright field microscopy, Zernike phase contrast and differential interference contrast mi...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

We thank Faekah Gohar for proofreading the manuscript. We thank Sonja Dufentester and Elke Weber for expert technical assistance.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Reagents
Azoxymethane (AOM)Sigma - Aldrich, Deisenhofen, GermanyA5486
Cell Culture FlaskGreiner Bio-One, Frickenhausen, Germany658170
Costar StripetteCorning Inc., New York, USA4488
Dextran sulphate sodium (DSS)TdB Consulatancy, Uppsala, SwedenDB001
DMEM/Ham's F12PAA Laboratories - Pasching - AustriaE15-813
EGFSigma - Aldrich, Deisenhofen, GermanySPR3196
Ethylenediaminetetraacetic acid (EDTA)Sigma - Aldrich, Deisenhofen, GermanyE 9884
Falcon Tube 50 mlBD Biosciences, Erembodegem, Belgium352070
Isopentane (2-Methylbutane)Sigma - Aldrich, Deisenhofen, GermanyM32631-1L
Methylene blueMerck, Darmstadt, Germany1159430025
Mitomycin CSigma - Aldrich, Deisenhofen, GermanyM4287
Microscope SlidesG. Menzel, Braunschweig, GermanyJ1800AMNZ
O.C.T. Tissue Tek compound                                 Sakura, Zoeterwonde, Netherlands4583
Pen/Strep/Amphotericin BLonza, Verviers, Belgium1558
Phosphate buffered saline, PBSLonza, Verviers, Belgium4629
RPMI 1640Lonza, Verviers, Belgium3626
Sodium Chloride 0.9%Braun, Melsungen, Germany5/12211095/0411
Standard dietAltromin, Lage, Germany1320
Tissue-Tek CryomoldSakura, Leiden, Netherlands4566
Trypsin EDTALonza, Verviers, Belgium7815
Vitro – CludR. Langenbrinck, Teningen, Germany04-0002 
 µ-Dish 35 mm with Culture-Insert, highibidi GmbH, Munich, Germany81176
DIC Lid for µ-Dishes, with a glass insertibidi GmbH, Munich, Germany80050
Equipment
MICROM HM550Thermo Fisher Scientific, Inc., Waltham, USA46320
Digital holographic microscope
ComponentModelCompany
Inverted MicroscopeiMICTill Photonics, Graefelfing, Germany
LaserCompass 315MCoherent GmbH, Luebeck, Germany
Microscope lensZeiss EC Plan Neofluar 10x/0.3Zeiss, Goettingen, Germany
CCD cameraDMK 41BF02The Imaging Source, Bremen, Germany

References

  1. Baumgart, D. C., Sandborn, W. J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 369 (9573), 1641-1657 (2007).
  2. Dieleman, L. A., et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 114 (3), 385-391 (1998).
  3. Florholmen, J. Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scand J Gastroenterol. 50 (1), 43-52 (2015).
  4. Merga, Y., Campbell, B. J., Rhodes, J. M. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy. Dig Dis. 32 (4), 475-483 (2014).
  5. Young, V. B., Kahn, S. A., Schmidt, T. M., Chang, E. B. Studying the Enteric Microbiome in Inflammatory Bowel Diseases: Getting through the Growing Pains and Moving Forward. Front Microbiol. 2, 144(2011).
  6. Atreya, R., Neurath, M. F. IBD pathogenesis in 2014: Molecular pathways controlling barrier function in IBD. Nat Rev Gastroenterol Hepatol. 12 (2), 67-68 (2015).
  7. Jones, M. K., Tomikawa, M., Mohajer, B., Tarnawski, A. S. Gastrointestinal mucosal regeneration: role of growth factors. Front Biosci. 4, 303-309 (1999).
  8. Burk, R. R. A factor from a transformed cell line that affects cell migration. Proc Natl Acad Sci U S A. 70 (2), 369-372 (1973).
  9. Singh, A., Nascimento, J. M., Kowar, S., Busch, H., Boerries, M. Boolean approach to signalling pathway modelling in HGF-induced keratinocyte migration. Bioinformatics. 28 (18), 495-501 (2012).
  10. Sakalar, C., et al. Pronounced transcriptional regulation of apoptotic and TNF-NF-kappa-B signaling genes during the course of thymoquinone mediated apoptosis in HeLa cells. Mol Cell Biochem. 383 (1-2), 243-251 (2013).
  11. Serada, S., et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis. 18 (11), 2169-2179 (2012).
  12. Turovskaya, O., et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 29 (10), 2035-2043 (2008).
  13. Perse, M., Cerar, A. Dextran sodium sulphate colitis mouse model: traps and tricks. J Biomed Biotechnol. 2012, 718617(2012).
  14. Lee, K., et al. Quantitative phase imaging techniques for the study of cell pathophysiology: from principles to applications. Sensors (Basel). 13 (4), 4170-4191 (2013).
  15. Bettenworth, D., et al. Quantitative stain-free and continuous multimodal monitoring of wound healing in vitro with digital holographic microscopy. PLoS One. 9 (9), 107317(2014).
  16. Sridharan, S., Macias, V., Tangella, K., Kajdacsy-Balla, A., Popescu, G. Prediction of prostate cancer recurrence using quantitative phase imaging. Sci Rep. 5, 9976(2015).
  17. Wang, Z., Tangella, K., Balla, A., Popescu, G. Tissue refractive index as marker of disease. J Biomed Opt. 16 (11), 116017(2011).
  18. Majeed, H., et al. Breast cancer diagnosis using spatial light interference microscopy. J Biomed Opt. 20 (11), 111210(2015).
  19. Lenz, P., et al. Digital holographic microscopy quantifies the degree of inflammation in experimental colitis. Integr Biol (Camb). 5 (3), 624-630 (2013).
  20. Popescu, G., et al. Optical imaging of cell mass and growth dynamics. Am J Physiol Cell Physiol. 295 (2), 538-544 (2008).
  21. Klokkers, J., et al. Atrial natriuretic peptide and nitric oxide signaling antagonizes vasopressin-mediated water permeability in inner medullary collecting duct cells. Am J Physiol Renal Physiol. 297 (3), 693-703 (2009).
  22. Jourdain, P., et al. Determination of transmembrane water fluxes in neurons elicited by glutamate ionotropic receptors and by the cotransporters KCC2 and NKCC1: a digital holographic microscopy study. J Neurosci. 31 (33), 11846-11854 (2011).
  23. Wirtz, S., Neufert, C., Weigmann, B., Neurath, M. F. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2 (3), 541-546 (2007).
  24. Bettenworth, D., et al. The tripeptide KdPT protects from intestinal inflammation and maintains intestinal barrier function. Am J Pathol. 179 (3), 1230-1242 (2011).
  25. Kemper, B., et al. Modular digital holographic microscopy system for marker free quantitative phase contrast imaging of living cells. Proc. SPIE. 6191, (2006).
  26. Kemper, B., von Bally, G. Digital holographic microscopy for live cell applications and technical inspection. Appl Opt. 47 (4), 52-61 (2008).
  27. Langehanenberg, P., von Bally, G., Kemper, B. Autofocusing in digital holographic microscopy. 3D Research. 2 (1), 1-11 (2011).
  28. Daimon, M., Masumura, A. Measurement of the refractive index of distilled water from the near-infrared region to the ultraviolet region. Applied optics. 46 (18), 3811-3820 (2007).
  29. Przibilla, S., et al. Sensing dynamic cytoplasm refractive index changes of adherent cells with quantitative phase microscopy using incorporated microspheres as optical probes. J Biomed Opt. 17 (9), 0970011-0970019 (2012).
  30. Kemper, B., et al. Integral refractive index determination of living suspension cells by multifocus digital holographic phase contrast microscopy. J Biomed Opt. 12 (5), 054009(2007).
  31. Carpenter, A. E., et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7 (10), 100(2006).
  32. Marquet, P., et al. Digital holographic microscopy: a noninvasive contrast imaging technique allowing quantitative visualization of living cells with subwavelength axial accuracy. Opt Lett. 30 (5), 468-470 (2005).
  33. Langehanenberg, P., Kemper, B., Dirksen, D., von Bally, G. Autofocusing in digital holographic phase contrast microscopy on pure phase objects for live cell imaging. Appl Opt. 47 (19), 176-182 (2008).
  34. Hanauer, S. B., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 359 (9317), 1541-1549 (2002).
  35. Colombel, J. F., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 132 (1), 52-65 (2007).
  36. Feagan, B. G., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 369 (8), 699-710 (2013).
  37. Sandborn, W. J., et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 369 (8), 711-721 (2013).
  38. Monteleone, G., et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med. 372 (12), 1104-1113 (2015).
  39. Vermeire, S., et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 384 (9940), 309-318 (2014).
  40. Sandborn, W. J., et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 367 (16), 1519-1528 (2012).
  41. Natividad, J. M., et al. Commensal and probiotic bacteria influence intestinal barrier function and susceptibility to colitis in Nod1-/-; Nod2-/- mice. Inflamm Bowel Dis. 18 (8), 1434-1446 (2012).
  42. Melgar, S., et al. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. Int Immunopharmacol. 8 (6), 836-844 (2008).
  43. Erben, U., et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol. 7 (8), 4557-4576 (2014).
  44. Bruckner, M., et al. Murine endoscopy for in vivo multimodal imaging of carcinogenesis and assessment of intestinal wound healing and inflammation. J Vis Exp. (90), (2014).
  45. Zhao, K., Wang, W., Guan, C., Cai, J., Wang, P. Inhibition of gap junction channel attenuates the migration of breast cancer cells. Mol Biol Rep. 39 (3), 2607-2613 (2012).
  46. Pavillon, N., et al. Early cell death detection with digital holographic microscopy. PLoS One. 7 (1), 30912(2012).
  47. Hindryckx, P., et al. Clinical trials in ulcerative colitis: a historical perspective. J Crohns Colitis. 9 (7), 580-588 (2015).
  48. Neurath, M. F., Travis, S. P. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 61 (11), 1619-1635 (2012).
  49. Bryant, R. V., Winer, S., Travis, S. P., Riddell, R. H. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis. 8 (12), 1582-1597 (2014).
  50. Marchal Bressenot, A., et al. Review article: the histological assessment of disease activity in ulcerative colitis. Aliment Pharmacol Ther. 42 (8), 957-967 (2015).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

Refractive Index MeasurementTissue Density AnalysisStain Free ImagingCell Culture MonitoringColitis Mouse ModelCaco 2 Cells

Related Articles